Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F R Appelbaum

Showing results (251-260 of 490) with videos related to

Pageof 49
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1993
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapyC H Weaver, F R Appelbaum, F B Petersen, et al.
Blood|December 1, 1993
Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantationJ Nemunaitis, F R Appelbaum, J W Singer, et al.
Bone Marrow Transplantation|December 2, 2000
Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicitiesT Furlong, R Storb, C Anasetti, et al.
Leukemia|May 3, 2016
Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemiaM Othus, B L Wood, D L Stirewalt, et al.
Blood|August 1, 1994
Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemiaR Storb, R Etzioni, C Anasetti, et al.
Pharmacoeconomics|June 7, 1994
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trialB R Luce, J W Singer, J M Weschler, et al.
Blood|December 1, 1992
The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboonsR G Andrews, W I Bensinger, G H Knitter, et al.
Blood|May 1, 1991
Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantationJ Nemunaitis, C D Buckner, F R Appelbaum, et al.
Transplantation Proceedings|February 1, 1987
Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host diseaseR Storb, H J Deeg, J Whitehead, et al.
Blood|October 1, 1993
Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factorC H Weaver, C D Buckner, K Longin, et al.
Pageof 49

Showing results (251-260 of 490) with videos related to

Sort By:
Pageof 49
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1993
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapyC H Weaver, F R Appelbaum, F B Petersen, et al.
Blood|December 1, 1993
Phase I trial with recombinant human interleukin-3 in patients with lymphoma undergoing autologous bone marrow transplantationJ Nemunaitis, F R Appelbaum, J W Singer, et al.
Bone Marrow Transplantation|December 2, 2000
Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicitiesT Furlong, R Storb, C Anasetti, et al.
Leukemia|May 3, 2016
Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemiaM Othus, B L Wood, D L Stirewalt, et al.
Blood|August 1, 1994
Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemiaR Storb, R Etzioni, C Anasetti, et al.
Pharmacoeconomics|June 7, 1994
Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trialB R Luce, J W Singer, J M Weschler, et al.
Blood|December 1, 1992
The ligand for c-kit, stem cell factor, stimulates the circulation of cells that engraft lethally irradiated baboonsR G Andrews, W I Bensinger, G H Knitter, et al.
Blood|May 1, 1991
Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantationJ Nemunaitis, C D Buckner, F R Appelbaum, et al.
Transplantation Proceedings|February 1, 1987
Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host diseaseR Storb, H J Deeg, J Whitehead, et al.
Blood|October 1, 1993
Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factorC H Weaver, C D Buckner, K Longin, et al.
Pageof 49